HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ravoxertinib

ERK1/2 Inhibitor

Also Known As:

(S)-1-(1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one; GDC-0994

Networked: 7 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - ravoxertinib: 7
  - Pyridines: 88
    - Pyridones: 14
      - ravoxertinib: 7

Experts

1.	Burris, Howard: 2 articles (10/2020 - 01/2020)
2.	Dokainish, Hatem: 2 articles (10/2020 - 01/2020)
3.	LoRusso, Patricia: 2 articles (10/2020 - 01/2020)
4.	Mueller, Lars: 2 articles (10/2020 - 01/2020)
5.	Murray, Elaine: 2 articles (10/2020 - 01/2020)
6.	Huang, Shih-Min A: 2 articles (01/2020 - 01/2017)
7.	Liu, Lichuan: 2 articles (01/2020 - 01/2017)
8.	Buzdin, Anton A: 1 article (01/2022)
9.	Ivanenko, Karina A: 1 article (01/2022)
10.	Khabusheva, Elmira R: 1 article (01/2022)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2020 - "GDC-0994 is an oral inhibitor of ERK1/2. A first-in-human, phase I dose escalation study of GDC-0994 was conducted in patients with locally advanced or metastatic solid tumors. " 01/01/2020 - "A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors." 01/01/2020 - "GDC-0994 had an acceptable safety profile and pharmacodynamic effects were observed by FDG-PET and in serial tumor biopsies. " 01/01/2017 - "Simulated responses to GDC-0994 monotherapy (overall response rate = 17%) accurately predicted results from a Phase 1 clinical trial regarding the number of responding patients (2/18) and the distribution of tumor size changes ("waterfall plot"). " 10/01/2020 - "This phase Ib trial evaluated the combination of cobimetinib (MEK inhibitor) and GDC-0994 (ERK inhibitor) in patients with locally advanced or metastatic solid tumors. "
2.	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 06/06/2023 - "Ravoxertinib Improves Long-Term Neurologic Deficits after Experimental Subarachnoid Hemorrhage through Early Inhibition of Erk1/2."
3.	Neurologic Manifestations (Neurological Manifestations) 06/06/2023 - "Ravoxertinib Improves Long-Term Neurologic Deficits after Experimental Subarachnoid Hemorrhage through Early Inhibition of Erk1/2."
4.	Neuroblastoma 01/01/2022 - "Using ERK1/2 and downstream kinase ELK1 reporter cell lines of lung cancer (H1299; NRASQ61K), colon cancer (HCT-116; KRASG13D), neuroblastoma (SH-SY5Y), and leukemia (U937), we examined the relationship between ERK inhibition and drug-induced toxicity for five ERK inhibitors: SCH772984, ravoxertinib, LY3214996, ulixertinib, and VX-11e, as well as one MEK inhibitor, PD0325901. "
5.	Neoplasm Metastasis (Metastasis) 12/04/2021 - "Moreover, Ravoxertinib could be a new therapeutical target for bone metastasis of CRC."

Related Drugs and Biologics

1.	Mitogen-Activated Protein Kinase Kinases (MEKs)
2.	ulixertinib
3.	cobimetinib
4.	MK-8353
5.	Phosphotransferases (Kinase)
6.	SCH772984
7.	mirdametinib
8.	LY3214996
9.	Vx-11e